Diligence memo · auto-generated · as of July 2, 2026
Immune Design Corp.
Immune Design Corp. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Immune Design Corp. operates in Biotechnology, based in SEATTLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Immune Design Corp. has raised $145M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $48M on 2013-10-16.
Most recent recorded round closed around 2013-10-16.
Valuation (modeled)modeled
Provath models Immune Design Corp. at approximately $2.0B (range $150M–$5.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.88× the median modeled value of Series C Biotechnology companies in 2013–2015 (41 peers) — value vs value, same stage and era. Within the normal band (88% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 12.7 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 94% of Biotechnology peers (4293 compared).
Modeled value ranks above 94% of those peers.
Closest niche peers: Antigenics LLC/DE, Naurex Inc., Fluidigm Corp, Tengion Inc, Spark Therapeutics, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.